Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues | Zendy

BL Johnston | Zendy; JM Conly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues

Author(s) -

BL Johnston,

JM Conly

Publication year - 2006

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2006/876252

Subject(s) - natalizumab , alemtuzumab , medicine , daclizumab , monoclonal antibody , adalimumab , infliximab , immunology , monoclonal antibody therapy , transplantation , monoclonal , hematopoietic stem cell transplantation , disease , antibody , multiple sclerosis , tumor necrosis factor alpha

In the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimmune disease or to prevent rejection in both solid organ and hematopoietic stem cell transplantation. While most of these agents have not been associated with increased infection rates, alemtuzumab and natalizumab have gained particular attention related to either the frequency or type of infection seen in some individuals who have received them

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research